Every few months another minister announces that Australia must rebuild its capacity to manufacture medicines onshore. The argument is sound and the pandemic made it unanswerable.
What gets far less attention is the workforce question sitting underneath it. Factories and funding announcements are the easy part. Finding several thousand people who can run a validated production line, write a regulatory submission or manage a clinical trial is considerably harder.
Key takeaways
Australia's medicines suppl.y has become a trade and sovereignty issue, not just a health one, after U.S. pharmaceutical lobbying against the Pharmaceutical Benefits Scheme.
Onshore manufacturing ambitions depend on a specialised workforce that takes years, not budget cycles, to build.
The roles in shortest supply are regulatory affairs, quality assurance, validation and clinical operations, none of which can be filled quickly.
Manufacturing employment is projected to grow to over a million by 2033, but the sector already reports persistent recruitment difficulty.
Workers moving into the sector from adjacent fields are one of the few realistic short-term sources of supply.
How medicines became a sovereignty question
The Pharmaceutical Benefits Scheme has existed since 1948 and is governed by the National Health Act 1953. Its central mechanism is the Pharmaceutical Benefits Advisory Committee, an independent expert body that assesses whether a medicine is cost-effective before the government agrees to subsidise it.
That mechanism is why Australians pay comparatively little for prescription medicines and it is precisely why parts of the U.S. pharmaceutical industry object to it. The U.S. pharmaceutical lobby has complained to the Trump administration that the PBS damages its profits and pushed for tariffs on pharmaceutical imports from Australia.
The Australian political response has been consistent across both major parties. Prime Minister Anthony Albanese has said the scheme is not up for negotiation, and successive governments have declared the PBS off the table in trade talks.
What that standoff exposes is a dependency. A country that imports most of its finished medicines has limited leverage when supply or pricing becomes a bargaining chip, which is the argument now driving interest in onshore capability.
Announcements are cheap, capability is not
Building a plant is a procurement problem with a known timeline. Staffing it is not.
Pharmaceutical manufacturing runs under Good Manufacturing Practice rules enforced by the Therapeutic Goods Administration. Every process must be validated, every deviation documented and every batch released by someone qualified to take responsibility for it.
That regulatory layer is what separates this from general manufacturing. You cannot redeploy a skilled production worker into a sterile fill-finish line in a fortnight, because the constraint is not manual skill but documented competence under an audited quality system.
The broader manufacturing picture gives some sense of scale. Jobs and Skills Australia data cited by the federal employment department puts manufacturing employment at around 914,500 people, with the sector projected to grow from 881,000 in May 2023 to 1.02 million by May 2033.
Growth of that order across an industry that already reports persistent recruitment difficulty is not a rounding error. It is a workforce planning problem, and the same pattern shows up in manufacturing jobs growth figures more generally, where job creation and the availability of qualified people are two different stories.
There is also a demographic issue. The employment department reports that most manufacturing workers are aged 43 or over and that women make up 28% of the industry, which is a narrow base from which to draw a rapid expansion.
Where the roles actually sit
The public imagination puts pharmaceutical work in a laboratory. Most of it is not there.
Regulatory affairs professionals prepare and defend submissions to the TGA and overseas regulators. Quality assurance and quality control staff maintain the systems that keep a manufacturing licence valid. Validation engineers prove that equipment and processes do what the documentation says they do.
Clinical operations is another substantial employer, covering trial coordinators, monitors and data managers who run studies to standards set well outside Australia. Medical affairs sits alongside it, translating clinical evidence for prescribers.
Then there is the commercial side, which is larger than most people assume. Market access specialists build the health economic case that a PBAC submission depends on, which makes them one of the few roles where commercial capability and public policy meet directly.
Medical devices and diagnostics operate under a parallel regulatory framework and compete for many of the same people. Digital health has added a further claim on the same limited pool.
Supply chain is the quiet one. Medicines have cold chain requirements, expiry dating and serialisation obligations that make distribution a technical function rather than a logistics commodity, and shortages over recent years have raised its profile considerably.
Manufacturing itself covers a wider range of work than the term suggests. Sterile fill-finish operators, process technicians, engineering and maintenance staff and warehouse personnel all work inside the same audited quality system, which means even the least specialised roles carry documentation obligations.
It is worth noting what this does to pay. Jobs and Skills Australia puts median manufacturing earnings at $1,654 per week against an all-industry median of $1,741, but pharmaceutical and medical technology roles generally sit well above the manufacturing average because of the regulatory qualification attached to them.
That divergence is the practical case for treating this as a distinct labour market rather than a subset of manufacturing. The skills are not interchangeable in either direction, and the wage data reflects it.
The bottleneck is people, not positions
Employers in this sector consistently report that specialist roles sit open for months. The reason is structural rather than cyclical.
These positions require a combination of scientific literacy, regulatory knowledge and documented experience that cannot be shortened by enthusiasm. Someone can be an excellent scientist and still be unqualified to sign off a batch release.
That is also why specialist recruiters occupy a real position in this market rather than an incidental one. PPD Search, which recruits across pharmaceutical, medical device and healthcare employers in Australia and New Zealand, collects pharmaceutical companies Australia jobs in one place, filterable by keyword, location and salary, alongside published salary benchmarking for the sector.
The firm operates from North Sydney with a presence in Melbourne and Brisbane, and runs separate divisions for permanent, contract and executive appointments. Salary benchmarking matters more here than in most sectors, because candidates and employers frequently disagree on what scarce regulatory experience is worth.
None of that solves the underlying shortage. It does make the market more legible, which is worth something when the constraint is matching a small number of qualified people to a growing number of roles.
What it means if you are considering the move
The realistic entry points are lateral. People move into pharmaceutical quality from food manufacturing, into clinical operations from nursing or research, and into regulatory affairs from science degrees plus postgraduate study.
Location is a real constraint. Most roles cluster in Sydney and Melbourne, with Brisbane a distant third, which limits the sector's ability to draw on the whole labour market.
The trade-off is worth naming honestly. The work is heavily documented and audited, which suits some people and frustrates others, and the sector rewards those who are comfortable with process rather than improvisation.
The policy gap nobody costs
There is a pattern in Australian industry policy where capital is funded and capability is assumed. Facilities get announced with dollar figures attached, while the training pipeline that would staff them gets a paragraph.
If the sovereign medicines argument is serious, and there are good reasons to think it should be, then the workforce component needs the same treatment as the capital component. That means funded pathways, recognised qualifications and a realistic account of how long it takes to produce someone who can hold a regulatory position.
Otherwise the outcome is predictable. New capacity gets built, competes for the same limited pool of experienced staff and bids up salaries without expanding the number of people who can do the work.
Conclusion
Australia's case for making more of its own medicines is stronger now than it has been in decades, and the political consensus around protecting the PBS is genuine.
The gap is not ambition or capital. It is several thousand people with regulatory, quality and clinical experience who do not currently exist in the numbers the plan requires, and who take years rather than budget cycles to produce.
FAQ
Why does Australia import most of its medicines?
Decades of offshoring moved production to lower-cost manufacturing hubs. Australia retains significant capability in some areas, including plasma products and vaccines, but relies heavily on imports for finished generic medicines.
What is the PBS and why is it contested internationally?
The Pharmaceutical Benefits Scheme subsidises prescription medicines for Australian residents, using an independent committee to assess cost-effectiveness before listing. Parts of the U.S. pharmaceutical industry argue this suppresses prices and have lobbied for trade pressure in response.
Which pharmaceutical roles are hardest to fill in Australia?
Regulatory affairs, quality assurance, validation and clinical operations are consistently reported as difficult. These roles require documented experience under audited quality systems, which cannot be acquired quickly.
Do you need a science degree to work in the sector?
Not for every role. Commercial, market access, supply chain and project management positions draw from wider backgrounds, though technical and regulatory roles generally require relevant scientific qualifications.
Where are most Australian pharmaceutical jobs located?
Sydney and Melbourne account for the majority, reflecting where company headquarters and manufacturing sites are concentrated, with Brisbane a smaller third market.
